

Information for Colorado Prescribers of Prescription Drugs Provided Pursuant to Colorado House Bill 19-1131

Diabetes Products

Marketed Prescription Drug

WAC* Price

ADMELOG® (insulin lispro injection) 100 units/mL (U-100) 3 mL Vial	\$ 39.23 per multiple-dose vial
ADMELOG® (insulin lispro injection) 100 units/mL (U-100) 10 mL Vial	\$ 98.07 per multiple-dose vial
ADMELOG® SoloStar® (insulin lispro injection) 100 units/mL (U-100) 3 mL Pen	\$ 189.35 per 5 prefilled pen
APIDRA® (insulin glulisine injection) 100 units/mL (U-100) 10 mL Vial	\$ 283.95 per multiple-dose vial
APIDRA® SoloStar® (insulin glulisine injection) 100 units/mL (U-100) 3 mL Pen	\$ 548.52 per 5 prefilled pens
LANTUS® (insulin glargine injection) 100 units/mL (U-100) 10 mL Vial	\$ 283.56 per multiple-dose vial
LANTUS® Novaplus® (insulin glargine injection) 100 units/mL (U-100) 10 mL Vial	\$ 283.56 per multiple-dose vial
LANTUS® SoloStar® (insulin glargine injection) 100 units/mL (U-100) 3 mL Pen	\$ 425.31 per 5 prefilled pens
LANTUS® SoloStar® Novaplus® (insulin glargine injection) 100 units/mL (U-100) 3 mL Pen	\$ 425.31 per 5 prefilled pens
SOLIQUA® 100/33 (insulin glargine and lixisenatide injection) 100 units/mL & 33 mcg/mL in 3 mL Pen	\$ 808.05 per 5 prefilled pens
TOUJEO® SoloStar® (insulin glargine injection) 300 units/mL (U-300) 1.5mL Pen	\$ 388.72 per 3 prefilled pens
TOUJEO® Max SoloStar® (insulin glargine injection) 300 units/mL (U-300) 3mL Pen	\$ 518.30 per 2 prefilled pens

Your patients' out of pocket cost may be different

Below please find as applicable three generic prescription drugs**

No generics applicable to the above prescription drugs

***Wholesale Acquisition Cost (WAC)** as published by FDB represents the manufacturer's published catalog or list price for a drug product to wholesalers as reported to FDB by the manufacturer. WAC does not represent actual transaction prices and does not include prompt pay or other discounts, rebates or reductions in price. FDB does not perform any independent investigation or analysis of actual transaction prices for purposes of reporting WAC. FDB relies on manufacturers to report or otherwise make available the values for the WAC.

For more information about First Databank's drug pricing policy, visit

<https://www.fdbhealth.com/drug-pricing-policy>

****The USC (Uniform System of Classification) Therapeutic Classification** schema was used to determine similar generic drugs. The **HCFA Drug Category of "Non-Innovator Multi-source"** as supplied on the CMS (formerly HCFA) quarterly update was used to determine the generic status of the drug products. This list does not imply that the generic prescription drugs on this form are interchangeable or have the same efficacy or safety. Please refer to each product's FDA-approved label and indication for further information.